Functional assessment of pathological α-syn and Aβ species in LBD
LBD 中病理 α-syn 和 Aβ 物种的功能评估
基本信息
- 批准号:10686906
- 负责人:
- 金额:$ 57.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-20 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AllelesAlzheimer&aposs DiseaseAmyloid beta-ProteinAutophagocytosisAutopsyBiochemicalBiologicalBiological AssayBrainBrain regionCell modelCellsCharacteristicsClinicalCognitive deficitsCollaborationsComplementComplexDementiaDementia with Lewy BodiesDevelopmentDiagnosticDiseaseEndosomesEnzymesGeneticGenetic RiskGenetic VariationHealthHumanImmunoassayImpairmentIndividualInduced pluripotent stem cell derived neuronsKnowledgeLewy BodiesLewy Body DementiaLipidsLysosomesMeasuresMembraneMethodsMolecular ConformationMutationNeuronsParkinson DiseaseParkinson&aposs DementiaPathologicPathway interactionsPatientsPositioning AttributeProcessProteinsProteomicsReporterResearch PersonnelScanningSenile PlaquesSlideStructureSubcellular FractionsSystemTissuesToxic effectValidationabeta accumulationalpha synucleinarmbeta pleated sheetbrain tissuedementia riskgenetic risk factorglucosylceramidasein vivolipidomicsmotor deficitmotor symptomneuropathologyneurotoxicnovelphosphoneuroprotein 14prion-likeprotein structureresponsesingle moleculestructural determinantssuperresolution microscopysynergismtranscriptomics
项目摘要
ABSTRACT
Elucidation of underlying disease mechanisms in Lewy body dementia requires the systematic characterization
of disease-specific changes in LBD brain tissue. The combination of dementia and motor symptoms at the
clinical level is reflected in the neuropathology by the accumulation of alpha-synuclein (α-syn) in Lewy bodies
and beta-amyloid (Aβ) in amyloid plaques. Both Aβ and α-syn are capable of aggregating into oligomers, fibrils,
and beta sheets, but the aggregates that form are extremely heterogeneous in terms of both structure and
function. The identification of which specific subspecies of the proteins are neurotoxic or support aggregation is
poorly understood and as a result development of diagnostics and treatments that depend on knowledge of
protein structure has been slow. Recent studies have suggested a ”seeded” or “prion-like” propagation for both
α-syn and Aβ, indicating that abnormal conformations may ‘spread’ from diseased to healthy cells. While
synthetic seeds of α-syn and Aβ confer toxicity in cells through various mechanisms, it is well known that the
exact method of preparing these species influences their bioactivity to a high degree. Herein we take the next
important step to analyze the actual subspecies from post-mortem brains, to define and compare aggregates,
and identify mechanisms of toxicity and spreading underlying the selective regional vulnerabilities. We will
extract soluble and insoluble α-syn and Aβ species from neuropathologically confirmed LBD brains with or
without genetic LBD risk factors for structural and functional characterization. We will assess load and
distribution of α-syn and Aβ subspecies and will detail their characteristics including size, structure and self-
templating capabilities (Aim 1). The critical involvement of autophagy-lysosomal pathways in LBD is
emphasized by the underlying genetic risks for LBD. Besides mutations in glucocerebrosidase (GBA) that
interfere with lysosomal functions, it is well established that individuals with the APOE ϵ4 allele have a 6-fold
greater risk for DLB. We will assess alterations in lysosome function in LBD brain and determine their response
and contribution to processing, aggregation, and toxicity of α-syn and Aβ subspecies (Aim 2). We will use
patients’ iPSC-derived neurons with different genetic risk factors to functionally validate the contribution to
aggregation, toxicity and spreading of α-syn and Aβ (Aim 3). The expertise of this group of investigators
synergizes to identify differences in structure and function of subspecies, to investigate mechanisms of
aggregation and toxicity, and to unravel the contributions of the genetic variations and alterations in selective
autophagy pathways to regional vulnerabilities. This puts us in a unique position to complement the studies of
Projects 1, 2, and 3 of this CWOW at multiple levels and towards the full characterization of α-syn and Aβ
subspecies.
摘要
阐明路易体痴呆的潜在疾病机制需要系统表征
LBD脑组织的疾病特异性变化。老年痴呆症和运动症状的结合,
临床水平在神经病理学中通过路易体中α-突触核蛋白(α-syn)的积累来反映
和淀粉样斑块中的β-淀粉样蛋白(Aβ)。Aβ和α-syn都能够聚集成寡聚体、原纤维,
和β片层,但形成的聚集体在结构和
功能确定蛋白质的哪些特定亚种具有神经毒性或支持聚集,
人们对此知之甚少,因此,诊断和治疗的发展依赖于对
蛋白质结构缓慢。最近的研究表明,这两种病毒都是通过“种子”或“朊病毒样”传播的。
α-syn和Aβ,表明异常构象可能从患病细胞“传播”到健康细胞。而
α-syn和Aβ的合成种子通过各种机制在细胞中赋予毒性,
制备这些物种的精确方法在很大程度上影响它们的生物活性。在此,我们采取下一个
重要的一步,分析实际亚种从死后的大脑,以确定和比较聚集,
并查明某些区域脆弱性的毒性和扩散机制。我们将
从神经病理学证实的LBD脑中提取可溶性和不溶性α-syn和Aβ物质,
没有遗传LBD风险因素的结构和功能表征。我们将评估负载,
α-syn和Aβ亚种的分布,并将详细介绍它们的特征,包括大小,结构和自我
模板功能(目标1)。自噬-溶酶体途径在LBD中的关键参与是
LBD的潜在遗传风险所强调的。除了葡萄糖脑苷脂酶(GBA)的突变,
干扰溶酶体功能,已经确定具有APOE β 4等位基因的个体具有6倍的
DLB的风险更大。我们将评估LBD脑中溶酶体功能的改变,并确定其反应
以及对α-syn和Aβ亚种的加工、聚集和毒性的贡献(目的2)。我们将使用
患者的iPSC衍生神经元具有不同的遗传风险因素,以功能验证对
α-syn和Aβ的聚集、毒性和扩散(目的3)。这组调查人员的专业知识
协同作用,以确定亚种的结构和功能的差异,研究机制,
聚集和毒性,并解开遗传变异的贡献和改变,选择性
区域脆弱性的自噬途径。这使我们处于一个独特的位置,以补充研究,
该CWOW的项目1、2和3在多个水平上,并对α-syn和Aβ进行全面表征
亚种。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pamela J McLean其他文献
Pamela J McLean的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pamela J McLean', 18)}}的其他基金
Mitochondrial Sirtuin 3 in Parkinson's disease
线粒体 Sirtuin 3 在帕金森病中的作用
- 批准号:
10409706 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Mitochondrial Sirtuin 3 in Parkinson's disease
线粒体 Sirtuin 3 在帕金森病中的作用
- 批准号:
10686813 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Functional assessment of pathological α-syn and Aβ species in LBD
LBD 中病理 α-syn 和 Aβ 物种的功能评估
- 批准号:
10237303 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Mitochondrial Sirtuin 3 in Parkinson's disease
线粒体 Sirtuin 3 在帕金森病中的作用
- 批准号:
10348483 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Functional assessment of pathological α-syn and Aβ species in LBD
LBD 中病理 α-syn 和 Aβ 物种的功能评估
- 批准号:
10022185 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Functional assessment of pathological α-syn and Aβ species in LBD
LBD 中病理 α-syn 和 Aβ 物种的功能评估
- 批准号:
10478195 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Mitochondrial Sirtuin 3 in Parkinson's disease
线粒体 Sirtuin 3 在帕金森病中的作用
- 批准号:
9753438 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Mitochondrial Sirtuin 3 in Parkinson's disease
线粒体 Sirtuin 3 在帕金森病中的作用
- 批准号:
10161872 - 财政年份:2019
- 资助金额:
$ 57.57万 - 项目类别:
Extracellular alpha-synuclein in Parkinson's Disease
帕金森病中的细胞外 α-突触核蛋白
- 批准号:
8234547 - 财政年份:2011
- 资助金额:
$ 57.57万 - 项目类别:
Extracellular alpha-synuclein in Parkinson's Disease
帕金森病中的细胞外 α-突触核蛋白
- 批准号:
8695502 - 财政年份:2011
- 资助金额:
$ 57.57万 - 项目类别: